Pharma and Life Sciences CTO Jobs in San Francisco

02:08 / recovery bridge

The laboratory system is restored, every final result is visible and the audit trail cannot prove which calculation ran before the outage

A cloud-hosted laboratory platform returns after a security event. Users can see approved results and electronic signatures. The restored database lacks part of the event history, one interface replayed messages, and analysts used controlled paper during downtime. Manufacturing wants to resume a time-sensitive decision.

The CTO should not decide product disposition or regulatory sufficiency. The technology decision is which record states are trustworthy enough for qualified owners to act, which remain quarantined and what evidence must be reconstructed. Availability, integrity, authenticity, completeness and business continuity are different claims.

FDA's electronic-record and data-integrity materials make the underlying record, metadata and lifecycle central. A screenshot of the right value is not the same as a reliable electronic record. The CTO mandate therefore starts with a decision-release protocol, not a recovery-time dashboard.

This page was compiled on 17 August 2026. It identifies no company, participant, product, batch, system, supplier, incident or vacancy.

Eleven-link record chain

Purpose, predicate, source, identity, time, method, version, audit, signature, review and retention must survive the restore together

Ask the candidate to release the chain in stages. Which system returns first matters less than which qualified decision can resume without concealing an unresolved record condition.

Record constitution

The Charter should name the authoritative record before it names the platform, cloud or transformation programme

Map legal entities, IND sponsor or applicant, research sites, laboratories, manufacturers, quality units, digital-health suppliers, cloud providers, security operations and data processors. For each consequential record, identify creator, custodian, predicate owner, system, interfaces, signature, review, retention and downstream decision.

Allocate board, CEO, CTO, clinical, regulatory, quality, manufacturing, security, privacy, legal and disclosure authority. The CTO owns architecture, controls and technical facts while another function may own clinical meaning, product release, regulatory position or materiality decision.

Name the first restore, cloud release, remote-data use and cyber escalation the mandate must govern. A board cannot hold the CTO accountable for trustworthy records while denying audit access, supplier rights or authority to stop a deployment.

Market zero / no implied technology search

Zero authorised Charters support no represented CTO vacancy, USD package, system weakness or incident inference

Pharma and Life Sciences CTO Jobs in San Francisco describes a mandate category. A breach notice, clinical technology announcement, cloud migration or regulatory filing does not prove an unannounced appointment.

Reward varies with product and trial stage, regulated-record perimeter, manufacturing scope, cyber accountability, platform complexity, team, public status, location and equity instrument. Zero authorised comparators cannot support a precise USD range.

Membership funds assessment, bounded verification and consent-led matching. It creates no system access, technical endorsement, interview or appointment.

Part 11 reliance map

The company prints a PDF for approval and relies on the electronic audit history whenever the decision is challenged

FDA's Part 11 scope guidance discusses electronic records maintained or submitted under predicate-rule requirements and recommends determining in advance whether the electronic or paper record is relied upon to perform regulated activity. It also explains the status of guidance and identified enforcement discretion.

Give the candidate a synthetic workflow where the signed PDF contains the final value but the electronic system holds calculations, changes, access events and review comments. Ask which complete record the company relies on, which predicate owner decides and how copies remain accurate and complete.

The CTO should not invoke Part 11 as a universal checklist or use enforcement discretion as permission to ignore underlying requirements. The evidence is a documented record decision, risk-based controls and an operating practice that matches the declared source of truth.

Remote-data missingness

The wearable uploads ninety-eight percent of readings and the missing two percent occurs during the clinical event the endpoint is meant to capture

FDA's final digital-health-technology guidance discusses fit-for-purpose form, function, context of use, verification, validation, data and participant considerations for remote acquisition in clinical investigations. Actual protocol and endpoint decisions belong to qualified clinical, statistical and regulatory owners.

Use a fictional device, smartphone, network, participant and vendor cloud. Map measurement, time, identity, firmware, local storage, transfer, transformation, missingness, alert, source access, investigator review and analysis dataset.

Now reveal that the device clocks drift after an update and the vendor imputes short gaps. The CTO should expose versions, affected population, raw and derived data, reversibility and escalation. A high upload percentage cannot answer whether the missing data are informative.

Laboratory metadata break

The result is in specification and its original run, aborted sequence and manual reintegration disappear from the report

FDA's data-integrity guidance describes completeness, consistency and accuracy, contextual metadata and the full data lifecycle. Give the candidate synthetic chromatographic data with a final passing result, earlier incomplete run, processing changes and a report that excludes the event history.

The CTO should preserve raw data, metadata, method and version, user actions, audit trail, exception, processing rationale and review access. Quality and laboratory owners determine the investigation and product consequence.

Ask which system design allowed an incomplete representation to appear complete, how retrospective review is bounded, and what preventive control changes behaviour. Installing an audit trail is not enough if nobody can retrieve, interpret or review the events that matter.

Cloud release collision

The supplier patches a critical vulnerability and changes the rounding logic in a workflow used to support a regulated decision

Provide a synthetic SaaS service with shared infrastructure, release channels, feature flags, validation evidence, incident commitments, data export and a narrow rollback window. Security wants immediate deployment; the process owner needs to understand the calculation change.

The CTO should classify affected intended use, records, configurations, interfaces and decisions. Separate security urgency, functional change, quality assessment, testing, approval, release, monitoring, fallback and evidence. The qualified business and quality owners retain acceptance.

Now make rollback restore the old vulnerability. Ask for a controlled alternative rather than a false choice between unsafe delay and unassessed change. Supplier speed becomes company risk unless the contract and architecture permit evidence-led deployment.

Cyber materiality packet

The attacker copied research files, no production system was encrypted and nobody can yet establish whether a consequential record changed

The SEC's final cybersecurity rules address disclosure of material incidents and periodic information about cyber risk management, strategy and governance for covered public companies. Actual materiality and disclosure require designated management, securities counsel and governance.

The CTO should build a fact packet rather than declare the legal outcome: affected entities and systems, record purpose, confidentiality, integrity and availability, actor and persistence, exfiltration evidence, alteration uncertainty, containment, recovery, operational and financial consequence, third parties and next update.

Separate what is observed, inferred and unknown. Research-file theft, participant data, product records, intellectual property and production availability may carry different consequences. The board needs uncertainty early enough to decide, not a final technical report after every option expires.

Restore acceptance matrix

Backups recover the database, interfaces replay three days and controlled paper records cannot be reconciled by system timestamp

Use a synthetic outage across laboratory, manufacturing, identity, integration and reporting systems. Define recovery point, recovery time, backup immutability, credential state, configuration, interface queue, manual procedure, electronic signatures, record sequence and business release.

Restore into an isolated state. Reconcile object counts, hashes where appropriate, metadata, audit events, duplicate and missing messages, paper records, approvals and downstream use. Qualified process owners accept their records before regulated decisions resume.

The CTO should state residual uncertainty and a correction route. A disaster-recovery exercise that proves servers boot but never proves record and decision release is infrastructure theatre.

Ten technology reversals

Build the CTO dossier from records and decisions corrected under uncertainty, not platforms delivered on schedule

For each, state legal entity, record purpose, candidate authority, qualified owners, system state, evidence, failed assumption, decision, aggregate outcome, later correction and residual weakness. Explain which conclusion the CTO did not make.

References should verify the moment the candidate delayed an attractive deployment or narrowed a confident incident statement. Technical humility with a controlled next step is stronger than retrospective certainty.

Candidate questions

Direct answers for technology leaders considering an unadvertised Bay Area life sciences mandate

Acceptance record trace

Reconstruct one clinical record and one manufacturing record before accepting the digital-transformation promise

Map legal entities, sponsor or applicant, clinical and laboratory systems, manufacturers, quality units, digital-health suppliers, cloud services, identity, security, privacy and disclosure owners. Identify contracts, data rights and stop authority.

Choose one clinical record. Trace participant or source creation, device or entry, time, identity, transfer, transformation, metadata, missingness, investigator review, analysis dataset, signature, retention and submission use. Introduce a device update and network gap.

Choose one manufacturing or laboratory record. Trace raw data, method, version, calculation, audit history, exception, electronic signature, quality review, retention and product decision. Introduce an outage, manual record and interface replay.

Declare the Part 11 reliance decision and predicate-rule owner for each. Confirm scope and controls with qualified regulatory, quality and legal teams rather than applying a generic system label.

Run one cloud release that combines a critical security patch with changed regulated functionality. Verify supplier notice, intended use, assessment, test, approval, deployment, monitoring, rollback and evidence.

Rehearse a cyber event. Produce the technical fact packet, uncertainty and update clock for designated management, securities, legal, privacy, clinical, quality and board owners. Do not ask the CTO alone to decide materiality.

Restore from a controlled point and reconcile records, metadata, signatures, interfaces, manual work and downstream decisions before business release. Complete technology, security, quality, regulatory, privacy, legal, identity, reference, background and compensation diligence before resignation.